SEC Comment Letter 0000000000-22-012384 to Omega Therapeutics, Inc. (OMGA) (CIK 0001850838)
Omega Therapeutics, Inc. (OMGA) (CIK 0001850838)
Date: Nov. 15, 2022 · CIK: 0001850838 · Accession: 0000000000-22-012384
AI Filing Summary & Sentiment
File numbers found in text: 333-268254
Letter
United States securities and exchange commission logo November 15, 2022 Mahesh Karande President and Chief Executive Officer Omega Therapeutics, Inc. 20 Acorn Park Drive Cambridge, MA 02140 Re:Omega Therapeutics, Inc. Registration Statement on Form S-3 Filed November 8, 2022 File No. 333-268254 Dear Mahesh Karande: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Wesley C. Holmes
Show Raw Text
United States securities and exchange commission logo
November 15, 2022
Mahesh Karande
President and Chief Executive Officer
Omega Therapeutics, Inc.
20 Acorn Park Drive
Cambridge, MA 02140
Re:Omega Therapeutics, Inc.
Registration Statement on Form S-3
Filed November 8, 2022
File No. 333-268254
Dear Mahesh Karande:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Wesley C. Holmes